Bafna Pharmaceuticals Limited (BAFNAPH.NS)
INR 75.88
(-5.01%)
INR 75.88
(-5.01%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 229.93 Million INR | 52.13% |
| 2022 | 151.13 Million INR | 67.5% |
| 2021 | 90.23 Million INR | -40.0% |
| 2020 | 150.38 Million INR | 391.01% |
| 2019 | -51.67 Million INR | -111.21% |
| 2018 | 460.88 Million INR | 0.11% |
| 2017 | 460.39 Million INR | -42.25% |
| 2016 | 797.25 Million INR | 2.52% |
| 2015 | 777.65 Million INR | 18.03% |
| 2014 | 658.83 Million INR | -37.5% |
| 2013 | 1.05 Billion INR | 33.24% |
| 2012 | 791.13 Million INR | 231.49% |
| 2011 | 238.65 Million INR | -39.22% |
| 2010 | 392.67 Million INR | 40.48% |
| 2009 | 279.52 Million INR | 27.81% |
| 2008 | 218.7 Million INR | -7.33% |
| 2007 | 236.01 Million INR | 53.81% |
| 2006 | 153.44 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | 78.1 Million INR | -48.33% |
| 2023 Q2 | 87.21 Million INR | 11.67% |
| 2023 FY | 229.93 Million INR | 52.13% |
| 2023 Q4 | 229.93 Million INR | 192.39% |
| 2023 Q3 | 78.63 Million INR | -9.83% |
| 2022 Q4 | 151.13 Million INR | 0.0% |
| 2022 FY | 151.13 Million INR | 67.5% |
| 2022 Q2 | 164.42 Million INR | 9404.45% |
| 2022 Q1 | 1.73 Million INR | -98.08% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q2 | 23.21 Million INR | 28.72% |
| 2021 Q1 | 18.03 Million INR | -88.01% |
| 2021 Q4 | 90.23 Million INR | 1146.67% |
| 2021 FY | 90.23 Million INR | -40.0% |
| 2021 Q3 | 7.23 Million INR | -68.83% |
| 2020 Q2 | 23.25 Million INR | -72.58% |
| 2020 FY | 150.38 Million INR | 391.01% |
| 2020 Q4 | 150.38 Million INR | 0.0% |
| 2020 Q1 | 84.8 Million INR | 264.11% |
| 2019 Q3 | 24.69 Million INR | -94.45% |
| 2019 FY | -51.67 Million INR | -111.21% |
| 2019 Q1 | 27.13 Million INR | -94.11% |
| 2019 Q2 | 445.27 Million INR | 1541.16% |
| 2019 Q4 | -51.67 Million INR | -309.29% |
| 2018 FY | 460.88 Million INR | 0.11% |
| 2018 Q4 | 460.88 Million INR | 0.0% |
| 2018 Q1 | 29.51 Million INR | 0.0% |
| 2017 FY | 460.39 Million INR | -42.25% |
| 2016 FY | 797.25 Million INR | 2.52% |
| 2015 FY | 777.65 Million INR | 18.03% |
| 2014 FY | 658.83 Million INR | -37.5% |
| 2013 FY | 1.05 Billion INR | 33.24% |
| 2012 FY | 791.13 Million INR | 231.49% |
| 2012 Q2 | 432.86 Million INR | 0.0% |
| 2012 Q4 | 791.13 Million INR | 0.0% |
| 2011 FY | 238.65 Million INR | -39.22% |
| 2010 FY | 392.67 Million INR | 40.48% |
| 2009 FY | 279.52 Million INR | 27.81% |
| 2008 FY | 218.7 Million INR | -7.33% |
| 2007 FY | 236.01 Million INR | 53.81% |
| 2006 FY | 153.44 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Amrutanjan Health Care Limited | -248.79 Million INR | 192.42% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 1346.52% |
| Caplin Point Laboratories Limited | -5.5 Billion INR | 104.175% |
| FDC Limited | -57.75 Million INR | 498.139% |
| Gufic Biosciences Limited | 3.19 Billion INR | 92.802% |
| Hikal Limited | 7.96 Billion INR | 97.114% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 105.536% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 120.878% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -91.549% |
| Medico Remedies Limited | 78.67 Million INR | -192.249% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 96.266% |
| Par Drugs and Chemicals Limited | -366.53 Million INR | 162.731% |
| RPG Life Sciences Limited | -364.7 Million INR | 163.047% |
| Sequent Scientific Limited | 4.17 Billion INR | 94.497% |
| Shilpa Medicare Limited | 9.06 Billion INR | 97.465% |
| Sigachi Industries Limited | 859.94 Million INR | 73.262% |
| Themis Medicare Limited | 764.96 Million INR | 69.942% |
| Unichem Laboratories Limited | 931.91 Million INR | 75.327% |
| Venus Remedies Limited | -267.7 Million INR | 185.892% |
| Wanbury Limited | 1.1 Billion INR | 79.208% |
| ZIM Laboratories Limited | 983.6 Million INR | 76.623% |
| Lupin Limited | 19.38 Billion INR | 98.814% |
| Innova Captab Limited | 2.33 Billion INR | 90.148% |
| Ind-Swift Limited | 9.5 Billion INR | 97.582% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 93.03% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 93.774% |
| Solara Active Pharma Sciences Limited | 10.03 Billion INR | 97.708% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 104.587% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 76.437% |
| Morepen Laboratories Limited | -231.17 Million INR | 199.463% |
| Laurus Labs Limited | 24.35 Billion INR | 99.056% |
| Aarti Drugs Limited | 5.54 Billion INR | 95.856% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 108.089% |
| Alembic Limited | 66.9 Million INR | -243.697% |
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 94.052% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 105.366% |
| Vaishali Pharma Limited | 119.13 Million INR | -93.002% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 91.197% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 116.543% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 99.151% |
| Eris Lifesciences Limited | 13.8 Billion INR | 98.335% |
| Windlas Biotech Limited | -273.04 Million INR | 184.212% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 100.317% |
| Lincoln Pharmaceuticals Limited | -127.63 Million INR | 280.145% |
| Orchid Pharma Limited | -1.31 Billion INR | 117.501% |
| Albert David Limited | -278.36 Million INR | 182.6% |
| Hester Biosciences Limited | 2.29 Billion INR | 89.963% |
| Sakar Healthcare Limited | 790.93 Million INR | 70.929% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -58.601% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 109.793% |
| Divi's Laboratories Limited | -39.77 Billion INR | 100.578% |
| Mankind Pharma Limited | -1.74 Billion INR | 113.151% |
| Neuland Laboratories Limited | -214.05 Million INR | 207.416% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 91.85% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 94.122% |
| Wockhardt Limited | 18.27 Billion INR | 98.741% |
| Bal Pharma Limited | 1.26 Billion INR | 81.803% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 98.219% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 119.86% |
| Alkem Laboratories Limited | -1.6 Billion INR | 114.287% |
| Valiant Laboratories Limited | 649.9 Million INR | 64.62% |
| Ajanta Pharma Limited | -954.9 Million INR | 124.079% |
| Aarey Drugs & Pharmaceuticals Limited | 297.57 Million INR | 22.732% |
| Granules India Limited | 9.28 Billion INR | 97.524% |
| Medicamen Biotech Limited | 160.31 Million INR | -43.425% |
| Ipca Laboratories Limited | 11.41 Billion INR | 97.986% |
| Brooks Laboratories Limited | 49.48 Million INR | -364.652% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -397.572% |
| Piramal Enterprises Limited | 491.39 Billion INR | 99.953% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 99.278% |
| NATCO Pharma Limited | -5.81 Billion INR | 103.953% |
| Suven Life Sciences Limited | -1.63 Billion INR | 114.083% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 88.104% |
| Strides Pharma Science Limited | 23.25 Billion INR | 99.011% |
| Indoco Remedies Limited | 6.47 Billion INR | 96.45% |
| Alpa Laboratories Limited | 35.36 Million INR | -550.208% |
| Lasa Supergenerics Limited | 205.79 Million INR | -11.727% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 124.414% |